Related Experiment Video
Updated: Aug 9, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
[Prevention of arterial thromboembolisms in patients with atrial fibrillation]
Andreas Schuchert1, Thomas Meinertz
1Abteilung für Kardiologie, Medizinische Klinik, Universitätsklinikum Hamburg-Eppendorf. schuchert@uke.uni-hamburg.de
Insights
Patients with atrial fibrillation face a 5% annual ischemic stroke risk. Risk stratification guides antithrombotic therapy, balancing stroke prevention with bleeding risk for personalized treatment.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Context:
- Atrial fibrillation (AF) poses a significant annual ischemic stroke risk (5%).
- Antithrombotic therapy is crucial for preventing arterial thromboembolic events in AF patients.
- Balancing anticoagulation's benefits against bleeding risks is essential for individualized patient care.
Purpose:
- To outline risk stratification for antithrombotic therapy in atrial fibrillation (AF).
- To guide the selection and management of antithrombotic strategies based on stroke risk.
- To inform therapeutic decisions regarding anticoagulation and antiplatelet agents.
Summary:
- Patients are stratified into low (<2%), medium (2-6%), and high (>6%) annual stroke risk categories based on age and comorbidities.
- Low-risk patients may use aspirin or no antithrombotic therapy.
- High-risk patients require oral anticoagulation (INR 2.0-3.0), while intermediate-risk patients may also benefit from oral anticoagulation over aspirin.
- Management protocols differ for surgical procedures (interruption of anticoagulation) and cardioversion (pre- and post-procedure anticoagulation).
Impact:
- Optimized antithrombotic strategies for atrial fibrillation patients.
- Reduced risk of ischemic stroke and thromboembolic events.
- Improved patient outcomes through personalized risk-benefit assessment of anticoagulation.
Background:
Patients with atrial fibrillation have a 5% risk per year for ischemic stroke. The aim of antithrombotic therapy is to prevent arterial thromboembolic events. As anticoagulation increases the frequency of bleeding, the risk and benefits of this therapy have to be assessed for each patient.
Patients At Risk:
The patients can be classified as low risk (< 2% stroke/year), medium risk (2-6% stroke/year), and high-risk patients (> 6% stroke/year). Parameters for the risk stratification are the patient age and cardiac as well as non-cardiac diseases.
Prevention:
Patients with a low risk need no anticoagulation or can take aspirin. Patients with a high risk should receive oral anticoagulation with an INR range from 2.0 to 3.0. Newer guidelines recommend also for patients with intermediate level of stroke risk instead of aspirin the prescription of oral anticoagulation. Patients with a medium risk can interrupt the oral anticoagulation before surgery or invasive diagnostic procedures for 1 week, patients with a high risk should receive heparin. 3-4 weeks before and after cardioversion the standard therapy is oral anticoagulation.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Venous Thrombosis III: Interprofessional Care
01:30Venous Thrombosis IV: Nursing Management
01:27Pulmonary Embolism III: Nursing Management